# APPENDIX
# 2B

Pfizer's Response to ALLHAT, 20 April 2001
Appendix 2B: LIST OF DOXAZOSIN PROTOCOLS WITH RELEASED DATABASES (N=271)

| PROTOCOL | COMPARATIVE (Y or blank) | TITLE | DRUGS IN DATABASE | PLACEBO CONTROLLED? | BPH OR CARDIOVASCULAR |
|---|---|---|---|---|---|
| D421 | Y | 89CE28-0421: A SIXTEEN-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED DOSE-RESPONSE STUDY USING DOXAZOSIN TABLETS FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION | DOXAZOSIN/PLACEBO | Yes | B |
| D421L | | OPEN LABEL EXTENSION OF D421 | | | |
| D488 | Y | 90CE28-0488: A FOURTEEN-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RESPONSE STUDY USING DOXAZOSIN TABLETS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN NORMOTENSIVE PATIENTS | DOXAZOSIN/PLACEBO | Yes | B |
| D488L | | OPEN LABEL EXTENSION OF D488 | | | |
| D490 | Y | 90CE28-0490: A SIXTEEN-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-TITRATION STUDY USING DOXAZOSIN TABLETS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN NORMOTENSIVE PATIENTS | DOXAZOSIN/PLACEBO | Yes | B |
| D490L | | OPEN LABEL EXTENSION OF D490 | | | |
| D606 | Y | 92CE28-0606: A TWENTY-SIX WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-TITRATION STUDY WITH AN OPEN LABEL EXTENSION USING DOXAZOSIN TABLETS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | DOXAZOSIN/PLACEBO | Yes | B |
| D606L | | OPEN LABEL EXTENSION OF D606 | | | |
| I010 | Y | DAZ-NY-87-010: A LONG-TERM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DOXAZOSIN IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH). | DOXAZOSIN /PLACEBO | Yes | B |
| I015 | Y | DAZ-NY-87-015: A DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RESPONSE STUDY OF EFFICACY AND TOLERATION OF DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | DOXAZOSIN /PLACEBO | Yes | B |
| I016 | Y | DAZ-NY-87-016: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH). | DOXAZOSIN /PLACEBO | Yes | B |
| I017 | Y | DAZ-NY-87-017: A DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF ORAL TREATMENT WITH DOXAZOSIN VERSUS PLACEBO IN HYPERTENSIVE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH). | DOXAZOSIN /PLACEBO | Yes | B |
| DAZ-A-88-001 | Y | TO COMPARE THE ANTIHYPERTENSION EFFICACY AND SAFETY OF DOXAZOSIN VS ENALAPRIL WHEN ADMINISTERED ONCE DAILY . | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-A-89-001 | | EVALUATION OF EFFICACY AND TOLERATION OF SUPRESSIN IN PATIENTS WITH ESSENTIAL HYPERTENSION WITH SPECIAL REGARD TO LIPID METABOLISM AND CHD RISK FACTORS. | | | |
| DAZ-AR-96-001 | | DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AN OPEN BASELINE CONTROLLED STUDY. ARGENTINE EXPERIENCE | | | |
| DAZ-AR-96-002 | | DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. AN OPEN, NON COMPARATIVE, MULTICENTER STUDY. | | | |
| DAZ-AUS-88-001 | | COMBINED EFFECT OF DOXAZOSIN AND PINDOLOL ON BLOOD PRESSURE CONTROL AND LIPID CONCENTRATIONS IN PATIENTS WITH ESSENTIAL HYPERTENSION SELECTED FROM GENERAL PRACTICE | DOXAZOSIN /PINDOLOL | | |
| DAZ-AUS-88-002 | Y | A DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE COMPARATIVE AND COMBINED SAFETY AND EFFICACY OF DOXAZOSIN AND ENALAPRIL | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-AUS-89-005 | Y | A STUDY TO EVALUATE THE COMBINED EFFECTS OF A LOW CHOLESTEROL DIET AND EITHER DOXAZOSIN OR ENALAPRIL TREATMENT ON BLOOD LIPIDS IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND HYPERCHOLESTEROLAEMIA. | DOXAZOSIN /ENALAPRIL | No | C |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-AUS-90-002 | Y | A COMPARISON OF THE SAFETY AND EFFICACY OF ENALAPRIL AND DOXAZOSIN THERAPY | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-BAN-88-001 | | TO STUDY THE EFFICACY AND SAFETY OF DOXAZOSIN WHEN ADMINISTERED ONCE DAILY TO PATIENTS WITH MILD TO MODERATE HYPERTENSION | | | |
| DAZ-BRA-95-002 | | URODYNAMIC EVALUATION OF DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AN OPEN, BASELINE CONTROLLED, MULTICENTER STUDY IN UROLOGICAL PRACTICE. | | | |
| DAZ-BRA-96-001 | | A LARGE SCALE MULTICENTER STUDY EVALUATING THE EFFICACY AND TOLERABILITY OF DOXAZOSIN IN THE TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | | | |
| DAZ-CDN-86-001 | | TO DETERMINE THE EFFICACY OF POST-SYNAPTIC A1 RECEPTOR BLOCKADE DOXAZOSIN IN A POPULATION BASED PROGRAM FOR DIAGNOSIS AND TREATMENT OF MILD TO MODERATE HYPERTENSION. | | | |
| DAZ-CDN-87-002 | Y | TO COMPARE THE EFFICACY, SAFETY AND COMPLIANCE OF DOXAZOSIN VS ATENOLOL FOR THE TREATMENT OF MILD TO MODERATE HYPERTENSION | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-CDN-87-002E | | TO MONITOR AND RECORD THE HYPOTENSIVE, EFFICACY, TOLERATION, SAFETY OF DAZ IN PATIENTS WHO SUCCESSFULLY COMPLETES THE DAZ MAINTENANCE. | | | |
| DAZ-COL-96-001 | | DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA OPEN, MULTICENTER, NON COMPARATIVE, BASELINE CONTROLLED STUDY IN AMBULATORY UROLOGICAL PRACTICE. | | | |
| DAZ-CR-96-001 | | DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. AN OPEN STUDY. | | | |
| DAZ-CZ-97-001 | | DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. A CORRELATION BETWEEN THE I-PSS AN SPI/II SCORES IN CENTRAL & EASTERN EUROPE. | | | |
| DAZ-D-85-001 | Y | DOUBLE-BLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF DOXAZOSIN VS ENALAPRIL IN PATIENTS WITH MILD TO MODERATE HYPERTENSION | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-D-85-003 | Y | EFFICACY AND TOLERATION OF DOXAZOSIN VS HCTZ IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION OVER ON YEAR. | DOXAZOSIN /HYDROCHLOROTHIAZIDE | No | C |
| DAZ-D-86-001 | | COMBINATION OF THE BETA-ANTAGONIST DOXAZOSIN WITH AN INSUFFICIENT FIXED PRE-TREATMENT (DIFFERENTIATED BETWEEN SELECTIVE AND NON-SELECTIVE BETA-BLOCKADE) IN PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-D-86-006 | | CONTINUOUS AMBULATORY 24-HOUR BLOOD PRESSURE MEASUREMENT FOR CONTROL OF DOXAZOSIN THERAPY | | | |
| DAZ-D-87-007B | Y | DOUBLE-BLIND, COMPARATIVE STUDY TO INVESTIGATE THE EFFICACY AND TOLERATION OF DOXAZOSIN VS PROPRANOLOL AND THEIR INFLUENCE ON PARAMETERS OF LIPID METABOLISM IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION | DOXAZOSIN /PROPRANOLOL HYDROCHLORIDE | No | C |
| DAZ-D-88-110 | | OPEN, NONCOMPARATIVE STUDY TO ASSESS EFFICACY AND TOLERABILITY OF DOXAZOSIN IN 1600 OUTPATIENTS | | | |
| DAZ-D-89-202 | Y | DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFECT OF ANTIHYPERTENSIVE THERAPY WITH DOXAZOSIN AND NIFEDIPINE ON CARDIOVASCULAR RISK IN HIGH-RISK PATIENTS | DOXAZOSIN /NIFEDIPINE | No | C |
| DAZ-D-89-204 | | CLINICAL STUDY OF THE INFLUENCE OF DOXAZOSIN ON PROTEINURIA IN HYPERTENSIVE PATIENTS WITH RENAL INSUFFICIENCY | | | |
| DAZ-D-89-205 | | CLINICAL STUDY ON THE EFFECT OF DOXAZOSIN ON ANF SECRETION (ARTERIAL NATRIURETIC FACTOR) | | | |
| DAZ-D-89-PMS1(AB) | | AB - STUDY DOXAZOSIN | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-D-90-302 | | OPEN NON-COMPARATIVE PILOT STUDY OF THE EFFECT OF DOXAZOSIN ON GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS WITH HYPERTRIGLYCERIDAEMIA. | | | |
| DAZ-D-91-403 | Y | DOUBLE-BLIND, RANDOMIZED, COMPARATIVE PILOT STUDY ON THE INVESTIGATION OF THE EFFECT OF DOXAZOSIN ON LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH MILD TO MODERATE HYPERTENSION COMPARED TO LISINOPRIL. | DOXAZOSIN /LISINOPRIL | No | C |
| DAZ-D-AB-90 | | AB - STUDY DOXAZOSIN | | | |
| DAZ-D-AB-91 | | AB - STUDY DOXAZOSIN. | | | |
| DAZ-DK-86-002 | Y | 6 MONTHS DOUBLE-BLIND RANDOMIZED PARALLEL GROUP, MULTICENTER COMPARISON OF DOXAZOSIN AND BENDROFLUMETHIAZIDE IN PATIENTS WITH ESSENTIAL MILD TO MODERATE HYPERTENSION | BENDROFLUMETHIAZIDE /DOXAZOSIN | No | C |
| DAZ-DK-87-004 | Y | EVALUATION OF THE NEED FOR AND EFFECT OF BLADDER DRAINAGE AFTER OPERATION FOR GENITAL PROLAPSE AND URINARY INCONTINENCE. A RANDOMIZED STUDY OF DOXAZOSIN VERSUS PLACEBO AND SUPRAPUBIC DRAINAGE AND DEMEURE. | DOXAZOSIN /PLACEBO | Yes | B/Urology |
| DAZ-DK-87-005 | Y | 5 YEAR OPEN RANDOMIZED PARALLEL GROUP MULTICENTER FOLLOW-UP TRIAL COMPARING PATIENTS TREATED WITH CARDURA (DOXAZOSIN) AND CENTYL (BENDROFLUMETHIAZIDE) WITH POTASSIUM CHLORIDE AS MONOTHERAPY OR CARDURA (DOXAZOSIN) AND CENTYL (BENDROFLUMETHIAZIDE) WITH POTASSIUM CHLORIDE IN MILD TO MODERATE HYPERTENSION | CENTYL /DOXAZOSIN | No | C |
| DAZ-DK-94-001 | Y | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED CROSS-OVER STUDY OF THE ANTIANGINAL ANTI-ISCHEMIC AND METABOLIC EFFECTS OF DOXAZOSIN IN PATIENTS WITH ANGINA PECTORIS POSITIVE EXERCISE TEST AND NORMAL CORONARY ANGIOGRAMS ("SYNDROME X") | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-E-85-001 | Y | TOLERANCE AND LONG TERM STUDY OF ANTIHYPERTENSIVE EFFECT OF DOXAZOSIN AND ITS ACTION ON LIPIDS COMPARED WITH ATENOLOL. | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-E-85-002 | Y | EFFICACY AND SAFETY OF DOXAZOSIN VS. ENALAPRIL IN PATIENTS WITH ESSENTIAL MILD-MODERATE HYPERTENSION ASSOCIATED TO HYPERCHOLESTEROLEMIA. | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-E-87-002 | | TO ASSESSES THE THERAPEUTIC EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE HYPERTENSION | | | |
| DAZ-E-89-002 | Y | EFFICACY AND SAFETY OF DOXAZOSIN COMPARED WITH NITRENDIPINE IN PATIENTS WITH ESSENTIAL MILD TO MODERATE HYPERTENSION. | DOXAZOSIN /NITRENDIPINE | No | C |
| DAZ-E-90-001 | | AN OPEN,NON COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY. | | | |
| DAZ-E-91-006 | | MULTICENTER OPEN NON-COMPARATIVE STUDY OF EFFICACY AND TOLERANCE OF DOXAZOSIN IN HYPERTENSIVE SMOKERS OUTCOME PATIENTS. | | | |
| DAZ-E-91-007 | | OPEN STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF HIGH RISK HYPERTENSIVE PATIENTS | | | |
| DAZ-E-92-001 | | OPEN STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF ISOLATED SYSTOLIC HYPERTENSION IN ELDERLY PATIENTS (OVER 60). | | | |
| DAZ-E-94-001 | Y | AN OPEN, MULTICENTER COMPARATIVE STUDY OF 26 WEEKS DURATION OF THE EFFICACY, SAFETY AND TOLERATION OF DOXAZOSIN (1-8MG) VS. LISINOPRIL (5-20MG) IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION IN ELDERLY HYPERTENSIVE MALE PATIENTS WITH UNDERLYING SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN /LISINOPRIL | No | C |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-E-95-001 | Y | A DOUBLE-BLIND, CROSSOVER, COMPARATIVE STUDY OF DOXAZOSIN VERSUS ENALAPRIL IN HYPERTENSIVE CYCLOSPORINE-TREATED RENAL TRANSPLANT PATIENTS. | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-E-95-002 | | SINGLE BLIND NON COMPARATIVE STUDY OF AMBULATORY BLOOD PRESSURE MONITORING TO EVALUATE DOXAZOSIN BP EFFECTS BY TROUGH: PEAK RATIO OVER 24 HOURS. | | | |
| DAZ-E-95-004 | Y | A DOUBLE - BLIND, DOUBLE DUMMY, COMPARATIVE, PARALLEL STUDY TO EVALUATE EFFICACY AND SAFETY OF DOXAZOSIN VS. DILTIAZEM IN POSTMENOPAUSAL WOMEN WITH MILD TO MODERATE HYPERTENSIVE AND HYPERCHOLESTEROLEMIA | DILTIAZEM /DOXAZOSIN | No | C |
| DAZ-ECU-94-001 | | DOXAZOSIN IN THE TREATMENT OF ARTERIAL HYPERTENSION AND HYPERLIPIDEMIA | | | |
| DAZ-EG-87-001 | | TO ASSESS THE SAFETY AND EFFICACY OF DOXAZOSIN IN THE TREATMENT OF ESSENTIAL HYPERTENSION | | | |
| DAZ-EG-88-001 | | TO ASSESS THE SAFETY AND EFFICACY OF DOXAZOSIN ADMINISTERED ONCE DAILY TO PATIENT WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-EG-88-002 | | TO ASSESS THE SAFETY AND EFFICACY OF DOXAZOSIN ADMINISTERED ONCE DAILY FOR THE TREATMENT OF ESSENTIAL HYPERTENSION | | | |
| DAZ-EG-89-001 | | SINGLE BLIND STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSIVE PATIENTS WITH CONCOMITANT DIABETES MELLITUS | | | |
| DAZ-EG-94-001 | | AN OPEN STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | | | |
| DAZ-EG-95-001 | | AN OPEN STUDY OF THE EFFICACY SAFETY AND TOLERABILITY OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. | | | |
| DAZ-EG-95-002 | | AN OPEN STUDY OF THE EFFICACY SAFETY AND TOLERABILITY OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | | | |
| DAZ-EG-98-001 | | A MULTICENTER OPEN, BASELINE CONTROLLED STUDY OF EFFICACY, SAFETY AND TOLERATION OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA CONCURRENT WITH MALE ERECTILE DYSFUNCTION. | | | |
| DAZ-I-86-001 | Y | EFFICACY AND SAFETY OF DOXAZOSIN AND ATENOLOL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-I-87-001 | | THE EFFECTS OF DOXAZOSIN IN PATIENTS WITH MILD TO MODERATE HYPERTENSION COPD. | | | |
| DAZ-I-87-002 | Y | EFFICACY OF DOXAZOSIN AND ENALAPRIL COMBINED WITH A THIAZIDE DIURETIC IN HYPERTENSIVE PATIENTS. TO ASSESS POSTURAL EFFECTS AND COLLECT INFORMATION ON ALPHA-ADRENERGIC RECEPTORS IN COMPARISON WITH ACE | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-I-88-001 | | TO STUDY THE EFFICACY AND SAFETY OF ONCE A DAY ORAL DOXAZOSIN WHEN ADMINISTERED TO PATIENTS FOR LVH & ESSENTIAL HYPERTENSION | | | |
| DAZ-I-88-002 | Y | TO STUDY THE CHRONIC RENAL HEMODYNAMIC EFFECTS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS, AND THE INFLUENCE OF ALPHA - 1 ADRENOCEPTOR BLOCKADE ON SULPIRIDE INDUCED RENAL EFFECTS. | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-I-88-003 | Y | EVALUATING DOXAZOSIN VS ENALAPRIL IN THE TREATMENT OF ESSENTIAL HYPERTENSION AND ANGINA FOR SAFETY AND EFFICACY | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-I-89-001 | Y | EFFICACY OF DOXAZOSIN AND EVALUATION ON MILD TO MODERATE HYPERTENSION IN ELDERLY PATIENTS. | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-I-89-002 | Y | EFFECTS OF DOXAZOSIN AND NITRENDIPINE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND HYPERCHOLESTEROLEMIA. | DOXAZOSIN /NITRENDIPINE | No | C |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-I-89-003A | | OPEN STUDY ON THE SAFETY AND EFFICACY OF CARDURA DAZ MESILATE IN THE TREATMENT OF MILD TO MODERATE HYPERTENSIVE PATIENTS. | | | |
| DAZ-I-89-003B | | EFFECTS OF CARDURA (DOXAZOSIN MESILATE) IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. | | | |
| DAZ-I-91-001 | | EVALUATION OF THE EFFICACY AND TOLERATION OF CARDURA (DAZ) IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION IN PATIENTS WITH RENAL IMPAIRMENTS | | | |
| DAZ-I-91-002 | | EVALUATION OF THE EFFICACY AND TOLERABILITY OF CARDURA (DAZ) IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION IN PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-I-92-001 | | A COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF STANDARD DAZ TABLETS VS DAZ GITS IN THE TREATMENT OF PATIENTS SUFFERING FROM MILD- MODERATE HYPERTENSION | | | |
| DAZ-I-92-002 | | AN OPEN EFFICACY AND SAFETY SWITCH STUDY FROM STANDARD DAZ TABLETS TO DAZ GITS IN THE TREATMENT OF MILD/MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-I-92-003 | | DOUBLE-BLIND, DOUBLE-DUMMY, COMPARATIVE STUDY ON THE EFFICACY AND SAFETY OF DAZ STANDARD TABS VS DAZ GITS IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE ESSENTIAL ARTERIAL HYPERTENSION | | | |
| DAZ-I-92-005 | Y | A DOUBLE-BLIND RANDOMIZED STUDY TO ASSESS THE EFFECT OF DOXAZOSIN ON CORONARY FLOW RESERVE IN PATIENTS WITH SYNDROME X | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-I-94-001 | Y | EVALUATION OF THE REDUCTION IN THE RISK OF CORONARY HEART DISEASE (CHD) FOLLOWING DOXAZOSIN THERAPY IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION IN PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS | DOXAZOSIN /PLACEBO | No | C |
| DAZ-I-95-002 | | INCREASE IN THE LEFT VENTRICULAR MASS IN DIABETIC HYPERTENSIVE AND NORMOTENSIVE PATIENTS WITH AUTONOMIC NEUROPATHY, EFFECT OF DOXAZOSIN TREATMENT | | | |
| DAZ-II-94-001 | | DOXAZOSIN IN HYPERTENSION: AN OPEN, NON-COMPARATIVE, MULTICENTER STUDY TO DETERMINE EFFICACY AND SAFETY | | | |
| DAZ-IND-90-002 | | A NON COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS. | | | |
| DAZ-JP-90-001 | | EFFECTS OF DOXAZOSIN ON GLUCOSE AND LIPID METABOLISM IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-JP-90-002 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-JP-90-003 | | CLINICAL EVALUATION OF DOXAZOSIN ON THE CIRCADIAN BP VARIANCE, AND USEFULNESS OF PROLONGED DOXAZOSIN TREATMENT | | | |
| DAZ-JP-90-004 | | USEFULNESS OF REPLACEMENT THERAPY FROM PRAZOSIN TO DOXAZOSIN AND USEFULNESS OF DAZ IN ELDERLY HYPERTENSION. | | | |
| DAZ-JP-90-005 | | ANTIHYPERTENSIVE EFFECTS OF DOXAZOSIN ON CIRCADIAN BLOOD PRESSURE AND HEART RATE PATTERNS IN 24 HOURS AMBULATORY HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-90-006 | | USEFULNESS OF REPLACEMENT THERAPY FROM PRAZOSIN TO DAZ FOR THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-91-004 | | PREVENTION OF LVH BY LONGTERM TREATMENT WITH DOXAZOSIN (EVALUATION BY BODY SURFACE ECG MAPPING) | | | |
| DAZ-JP-91-005 | | USEFULNESS OF DOXAZOSIN IN ESSENTIAL HYPERTENSION PATIENTS WITH OBESITY AND HYPERLIPIDEMIA. | | | |
| DAZ-JP-91-006 | | CLINICAL USEFULNESS OF DOXAZOSIN IN HYPERTENSION PATIENTS WITH SYMPATHETIC HYPERACTIVITY | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-JP-91-007 | | ANTIHYPERTENSIVE EFFECTS OF DAZ ON CIRCADIAN BLOOD PRESSURE AND HEART RATE PATTERNS IN 24 HRS AMBULATORY HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-91-008 | | STUDIES ON THE EFFECT OF DAZ ON INSULIN SENSITIVITY IN PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-91-010 | | EVALUATION ON THE CIRCADIAN BP PATTERNS AND USEFULNESS OF DAZ ON LONG TERM TREATMENT IN PATIENTS WITH HYPERTENSION | | | |
| DAZ-JP-91-011 | | MEASUREMENT OF THE EFFECT OF DAZ ON THE CEREBRAL BLOOD FLOW IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-91-012 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CHRONIC RESPIRATORY DYSFUNCTION | | | |
| DAZ-JP-91-013 | | EFFECTS OF DAZ ON SERUM LIPOPROTEIN(A) LEVELS IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA | | | |
| DAZ-JP-91-014 | | EFFECT OF PROLONGED DOXAZOSIN TREATMENT ON GLUCOSE AND LIPID METABOLISM IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-JP-91-015 | | EFFECT OF PROLONGED DAZ TREATMENT IN HYPERTENSIVE PATIENTS WITH LVH (LEFT VENTRICULAR HYPERTROPHY) | | | |
| DAZ-JP-91-016 | | EFFECTS OF DAZ ON GLUCOSE METABOLISM IN HYPERTENSIVE PATIENTS WITH NIDDM | | | |
| DAZ-JP-92-001 | | USEFULNESS OF DAZ IN MONOTHERAPY IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA | | | |
| DAZ-JP-92-003 | | EFFECTS OF DAZ ON INSULIN SENSITIVITY AND GLUCOSE METABOLISM IN HYPERTENSIVE PATIENTS WITH OR WITHOUT JGT | | | |
| DAZ-JP-92-004 | | USEFULNESS OF PROLONGED DAZ MONOTHERAPY ON GLUCOSE AND LIPIDS METABOLISM IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-JP-92-005 | | EFFECTS OF PROLONGED DOXAZOSIN TREATMENT ON SECOND PREVENTION OF POST-SCLEROTHERAPY IN HYPERTENSIVE PATIENTS WITH ESOPHAGEAL VARICES. | | | |
| DAZ-JP-92-006 | | USEFULNESS OF DOXAZOSIN MONOTHERAPY ON GLUCOSE AND LIPIDS METABOLISM AND FIBRINOLYTIC SYSTEM IN PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-92-007 | | EFFECTS OF DAZ ON SERUM LIPID LEVELS IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-92-008 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSION PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE. | | | |
| DAZ-JP-92-009 | | EFFECT OF DOXAZOSIN ON GLUCOSE AND LIPIDS METABOLISM IN HYPERTENSIVE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE | | | |
| DAZ-JP-92-012 | | EFFECTS OF DAZ ON RENAL FUNCTION IN HYPERTENSIVE PATIENTS. | | | |
| DAZ-JP-92-015 | | EFFECT OF DAZ ON THE CEREBRAL BLOOD FLOW IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-92-016 | | CLINICAL EFFICACY OF DAZ ON LIPID METABOLISM AND PLATELET AFFREFATION IN HYPERTENSIVE SMOKERS. | | | |
| DAZ-JP-92-017 | | USEFULNESS OF DAZ IN HYPERTENSIVE PATIENTS WITH EARLY STAGE DIABETIC NEPHROPATHY | | | |
| DAZ-JP-92-020 | | CLINICAL EFFICACY OF DAZ ON HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA | | | |
| DAZ-JP-93-003 | | EFFECTS OF DOXAZOSIN ON SERUM LIPID LEVELS IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-007 | | EFFECTS OF DOXAZOSIN ON AUTONOMIC NERVOUS SYSTEM IN ELDERLY HYPERTENSIVE PATIENTS. | | | |
| DAZ-JP-93-008 | | ANTIHYPERTENSIVE EFFECTS AND SAFETY OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS. | | | |
| DAZ-JP-93-010 | | EFFECTS OF DAZ ON LIPID METABOLISM AND GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-JP-93-202 | | CLINICAL EFFICACY OF DAZ IN PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-93-205 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-93-207 | | CLINICAL EFFICACY OF DOXAZOSIN FOR THE LONG-TERM TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-93-208 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS | | | |
| DAZ-JP-93-209 | | ANTIHYPERTENSIVE EFFECTS OF DOXAZOSIN IN PATIENTS WITH ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-93-210 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSION | | | |
| DAZ-JP-93-211 | | USEFULNESS OF DOXAZOSIN IN PATIENTS WITH MILD-MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-JP-93-212 | | EFFECTS OF DOXAZOSIN ON GLUCOSE METABOLISM IN HYPERTENSIVE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE | | | |
| DAZ-JP-93-213 | | EFFECTS OF DOXAZOSIN ON GLUCOSE AND LIPID METABOLISM IN HYPERTENSIVE PATIENTS WITH D.M. | | | |
| DAZ-JP-93-215 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-93-216 | | EFFECTS OF DOXAZOSIN ON LIPID METABOLISM IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-217 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH OR WITHOUT MICTURITIONARY DISTURBANCE | | | |
| DAZ-JP-93-218 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-93-219 | | EFFECTS OF DOXAZOSIN ON LIPID METABOLISM AND GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS WITH D.M. OR HYPERLIPIDEMIA | | | |
| DAZ-JP-93-220 | | EFFECTS OF DOXAZOSIN IN QUALITY OF LIFE IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-221 | | LONG-TERM ANTIHYPERTENSIVE EFFECTS AND SAFETY OF DOXAZOSIN IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-222 | | LONG-TERM ANTIHYPERTENSIVE EFFECTS AND SAFETY OF DOXAZOSIN IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-223 | | EFFECTS OF DAZ ON LIPID AND GLUCOSE METABOLISM IN HYPERTENSIVE PATIENTS WITH DIABETES MELLITUS | | | |
| DAZ-JP-93-224 | | EFFECTS OF DAZ ON LIPID METABOLISM IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-225 | | EFFECTS OF DAZ ON LIPID METABOLISM IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-226 | | EFFECTS OF DAZ ON RENAL FUNCTION AND CIRCADIAN RHYTHM IN HYPERTENSIVE PATIENTS WITH IMPAIRED RENAL FUNCTION | | | |
| DAZ-JP-93-227 | Y | EFFECTS OF DAZ ON LIPID METABOLISM IN HYPERTENSIVE PATIENTS | DOXAZOSIN /TRICHLORMETHIAZIDE | No | C |
| DAZ-JP-93-228 | | EFFECTS OF DAZ IN LIPID METABOLISM AND CIRCADIAN RHYTHM IN HYPERTENSIVE PATIENTS | DOXAZOSIN /INDAPAMIDE /TRICHLORMETHIAZIDE | | |
| DAZ-JP-93-230 | | EFFECTS OF DAZ ON LIPID METABOLISM AND GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE | | | |
| DAZ-JP-93-231 | | USEFULNESS OF DAZ IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-93-232 | | EFFECTS OF DAZ ON LIPID METABOLISM AND GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-233 | | EFFECTS OF DAZ ON LIPID METABOLISM AND PLATELET AGGREGATION IN HYPERTENSIVE PATIENTS | | | |
| DAZ-JP-93-234 | | USEFULNESS OF DAZ IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-93-235 | | EFFECTS OF DAZ ON LIPID METABOLISM IN HYPERTENSIVE PATIENTS WITH HYPERLIPIDEMIA | | | |
| DAZ-JP-94-201 | | EFFECTS OF DOXAZOSIN ON RENAL FUNCTION IN ESSENTIAL HYPERTENSIVE PATIENTS WITH DIABETIC NEPHROPATHY IN EARLY STAGE | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-JP-94-203 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-94-204 | | EFFECTS OF DOXAZOSIN ON LIPID METABOLISM IN HYPERTENSIVE SMOKERS AND MORE SMOKERS | | | |
| DAZ-JP-94-206 | | CLINICAL USEFULNESS OF DOXAZOSIN IN POST MENOPAUSAL HYPERTENSIVE FEMALE WITH SENILE VAGINITIS | | | |
| DAZ-JP-94-207 | | EFFECTS OF DOXAZOSIN ON DYSURIA IN HYPERTENSIVE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA | | | |
| DAZ-JP-94-208 | | USEFULNESS OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH CEREBROVASCULAR DISORDERS IN CHRONIC STAGE | | | |
| DAZ-JP-94-209 | | EFFECTS OF DOXAZOSIN ON LIPID METABOLISM AND GLUCOSE TOLERANCE IN HYPERTENSIVE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE | | | |
| DAZ-JP-94-210 | | CLINICAL EFFICACY AND SAFETY OF DOXAZOSIN IN HYPERTENSIVE PATIENTS WITH SYNDROME X | | | |
| DAZ-JP-95-001 | | CLINICAL EVALUATION OF DOXAZOSIN ON DYSURIA IN HYPERTENSIVE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | | | |
| DAZ-JP-96-001 | Y | EVALUATION OF THE EFFECTS OF DOXAZOSIN ON LIPID METABOLISM IN HYPERTENSIVE CLIMACTERIC FEMALE PATIENTS IN COMPARISON WITH NIFEDIPINE. | DOXAZOSIN /ENALAPRIL MALEATE | No | C |
| DAZ-JP-96-002 | Y | EVALUATION OF THE EFFECTS OF DOXAZOSIN ON BLOOD PRESSURE & DYSURIA IN THE HYPERTENSIVE PATIENTS WITH BENIGN PROSTATIC HYPERTENSION PERPLASIA IN COMPARISON WITH ENALAPRIL. | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-K-84-001 | | AN OPEN STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSION IN GENERAL PRACTICE. | | | |
| DAZ-K-87-001 | | SAFETY AND EFFICACY OF DOXAZOSIN IN PATIENTS WITH HYPERTENSION USED AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS. | | | |
| DAZ-K-87-003 | | SAFETY AND EFFICACY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-K-88-001 | | HOSPITAL OUT PATIENT CLINIC OPEN STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-K-90-001 | Y | EFFECTIVENESS, SAFETY AND METABOLIC EFFECTS OF DOXAZOSIN IN HYPERTENSION COMPARED TO HCTZ. | DOXAZOSIN /HYDROCHLOROTHIAZIDE | No | C |
| DAZ-K-90-002 | | EFFICACY OF DOXAZOSIN (CARDURA) IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-K-90-003 | | CLINICAL EFFECTS OF DOXAZOSIN IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-K-95-003 | | DRUG USE INVESTIGATION OF CARDURA BY QUICK DOSE TITRATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | | | |
| DAZ-MAL-87-002 | | TO DETERMINE THE EFFICACY AND SAFETY OF DAILY DOSE OF DOXAZOSIN IN THREE PHASES WITH A TOTAL DURATION OF 30 WEEKS FOR EACH PATIENT WITH MILD TO MODERATE ESSENTIAL HYPERTENSION. PHASE I-4 WK BASELINE. PHASE II 10 WK TITRATION PHASE III 16-WK MAINTENANCE | | | |
| DAZ-MAL-90-001 | | EFFICACY OF DOXAZOSIN ON BLOOD PRESSURE IN SMOKERS WITH MILD-MODERATE ESSENTIAL HYPERTENSION. | | | |
| DAZ-MEX-86-001 | | TO DETERMINE THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE HYPERTENSION | | | |
| DAZ-MEX-86-002 | | TO ASSESS THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION | | | |
| DAZ-MEX-96-001 | | DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. AN OPEN BASELINE CONTROLLED STUDY IN HOSPITAL UROLOGICAL PRACTICE. | | | |
| DAZ-MOR-96-001 | | NON COMPARATIVE MULTICENTER STUDY ON THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERTROPHY. | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-MOR-96-002 | | NON COMPARATIVE MULTICENTER STUDY ON THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF HIGH BLOOD PRESSURE. | | | |
| DAZ-MOR-97-001 | | NON COMPARATIVE MULTICENTER STUDY ON THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERTROPHY. | | | |
| DAZ-N-91-003 | Y | EFFECT OF ANTIHYPERTENSIVE MEDICATION WITH DOXAZOSIN ON ENDURANCE EXERCISE PERFORMANCE IN SPORTING MEN. | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-N-94-001 | | ASSESSMENT OF ANTIOXIDATIVE EFFECT OF DAZ AND ITS HYDROXI-METABOLITES IN PATIENTS WITH MILD TO MODERATE HYPERTENSION ON DOXAZOSIN MONOTHERAPY. | | | |
| DAZ-N-95-002 | | A COMPARISON OF DOXAZOSIN IN THE GASTROINTESTINAL THERAPEUTIC SYSTEM (GITS) FORMULATION WITH DOXAZOSIN STANDARD FORMULATION FOR THE TREATMENT OF MILD TO MODERATE HYPERTENSION. | | | |
| DAZ-N-95-003 | Y | A COMPARISON OF DOXAZOSIN IN THE GASTROINTESTINAL THERAPEUTIC SYSTEM (GITS) FORMULATION WITH DOXAZOSIN STANDARD FORMULATION AND PLACEBO FOR THE TREATMENT OF MILD HYPERTENSION. | DOXAZOSIN/PLACEBO | Yes | C |
| DAZ-N/S/DK-95-001 | Y | A 15 WEEK, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DOXAZOSIN VS. DOXAZOSIN GITS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN/PLACEBO | Yes | B |
| DAZ-NL-86-001 | | EFFICACY AND SAFETY OF DOXAZOSIN IN LONG TERM TREATMENT IN PATIENTS WITH MILD MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-NY-83-008 | | TO EVALUATE THE HEMODYNAMIC EFFECTS OF DOXAZOSIN UPON ATTAINING BLOOD PRESSURE CONTROL IN MILD AND MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-NY-84-001 | | TO STUDY THE ANTI-HYPERTENSIVE EFFICACY AND SAFETY OF DOXAZOSIN WHEN ADMINISTERED ONCE DAILY TO PATIENTS WITH MILD AND MODERATE ESSENTIAL HYPERTENSION IN A GENERAL MEDICAL PRACTICE. | | | |
| DAZ-NY-85-003 | | TO DETERMINE THE EFFICACY AND SAFETY AND HEMODYNAMIC EFFECTS OF ACUTELY AND CHRONICALLY ADMINISTERED DOXAZOSIN IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. | | | |
| DAZ-NY-85-008 | | TO COMPARE THE PHARMACOKINETICS OF DOXAZOSIN AND DETERMINE WHETHER PRIOR FEEDING AFFECTS IT IN YOUNG AND OLD PATIENTS WITH HIGH BLOOD PRESSURE. | | | |
| DAZ-NY-87-006 | | TO ASSESS THE ANTI-HYPERTENSIVE EFFICACY AND SAFETY AND LIPID PROFILE OF ONCE DAILY DOXAZOSIN WHEN ADMINISTERED TO PATIENTS WITH MILD AND MODERATE HYPERTENSION NOT ADEQUATELY CONTROLLED BY ATENOLOL ONCE DAILY. | | | |
| DAZ-NY-87-009 | | A STUDY OF THE EFFECTS OF DOXAZOSIN ON BLOOD GLUCOSE, INSULIN SECRETION, AND INSULIN SENSITIVITY IN NORMAL MEN. | | | |
| DAZ-NY-87-011 | | TO DETERMINE THE CORONARY HEMODYNAMIC EFFECTS OF DOXAZOSIN IN MILD AND MODERATE ESSENTIAL HYPERTENSIVE SMOKERS WITH CORONARY DISEASE | | | |
| DAZ-NY-87-022 | Y | TO COMPARE THE ACUTE AND CHRONIC HEMODYNAMIC EFFECTS OF DOXAZOSIN VS. ATENOLOL IN PATIENTS WHO SMOKE WITH MILD AND MODERATE ESSENTIAL HYPERTENSION. | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-NY-87-023 | Y | TO COMPARE THE ACUTE PERIPHERAL HEMODYNAMIC EFFECTS OF DOXAZOSIN VS. ATENOLOL IN PATIENTS WITH MILD AND MODERATE ESSENTIAL HYPERTENSION WHO SMOKE. | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-NY-88-006 | | TO STUDY THE EFFECTS OF DOXAZOSIN ON PLASMA GLUCOSE AND INSULIN, AND TO DETERMINE THE INSULIN SENSITIVITY IN MILD AND MODERATE HYPERTENSION AND IN NON-INSULIN-DEPENDENT DIABETICS WITH MILD AND MODERATE HYPERTENSION | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-NY-89-003 | | EFFECTS OF DOXAZOSIN ON THE INSULIN SENSITIVITY OF ELDERLY PATIENTS WITH MILD AND MODERATE HYPERTENSION. | | | |
| DAZ-NY-90-001 | Y | THE EFFECT OF DOXAZOSIN AND ATENOLOL ON CHYLOMICRON-METABOLISM AND LIPOPROTEIN-SPECTRUM IN PATIENTS WITH HYPERTENSION | DOXAZOSIN/ATENOLOL | No | C |
| DAZ-NY-90-004 | Y | INFLUENCE OF CHANGING PLASMA LIPIDS ON THE PROGRESSION/REGRESSION OF ATHEROSCLEROSIS IN HYPERTENSIVE PATIENTS TREATED WITH DOXAZOSIN AND HCTZ. (ALSO THE EFFECTS ON CHOLESTEROL, FATTY ACID AND SERUM LIPIDS.) | DOXAZOSIN/HYDROCHLOROTHIAZIDE | No | C |
| DAZ-NY-90-008 | Y | A SINGLE BLIND COMPARISON OF THE METABOLIC EFFECTS OF DOXAZOSIN VS. ENALAPRIL TREATMENT IN HYPERTENSIVE PATIENTS WITH ELEVATED TRIGLYCERIDES | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-NY-90-009 | Y | AN OPEN COMPARISON OF THE METABOLIC AND RENAL EFFECTS OF DOXAZOSIN, ENALAPRIL AND NIFEDIPINE TREATMENT IN NON-INSULIN DIABETICS WITH HYPERTENSION. | DOXAZOSIN/ENALAPRIL/NIFEDIPINE | No | C |
| DAZ-NY-91-008 | Y | A SINGLE-BLIND CROSS OVER STUDY COMPARING THE EFFECTS OF DOXAZOSIN AND ENALAPRIL ON THE SEXUAL FUNCTION OF HYPERTENSIVES AND HYPERTENSIVES WITH NON-INSULIN DEPENDENT DIABETES | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-NY-92-001 | Y | RELATIONSHIP BETWEEN INSULIN RESISTANCE AND PERIPHERAL VASCULAR RESISTANCE IN ESSENTIAL HYPERTENSION: EFFECTS OF TWO DIFFERENT CHRONIC PHARMACOLOGICAL TREATMENTS. | DOXAZOSIN /NIFEDIPINE GITS | No | C |
| DAZ-NY-92-002 | Y | A DOUBLE BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF DOXAZOSIN VS. PLACEBO AND MORNING VS. EVENING DOSING IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA (BPH). | DOXAZOSIN/PLACEBO | Yes | B |
| DAZ-NY-92-005 | Y | A DOUBLE-BLIND COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN AND ENALAPRIL IN THE TREATMENT OF MILD AND MODERATE HYPERTENSION IN OLDER HYPERTENSIVE MALE PATIENTS WITH UNDERLYING SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN/ENALAPRIL/PLACEBO | No | C |
| DAZ-NY-92-008 | Y | A DOUBLE BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF DOXAZOSIN VS. ALFUZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN/ALFUZOSIN | No | B |
| DAZ-NY-92-009 | Y | A DOUBLE-BLIND, DOUBLE-DUMMY PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOXAZOSIN VS. FINASTERIDE VS. COMBINATION THERAPY IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN/FINASTERIDE/PLACEBO | Yes | B |
| DAZ-NY-95-001 | | A 15 WEEK PROSPECTIVE RANDOMIZED DOUBLE-BLIND TRIAL OF THE EFFICACY AND SAFETY OF DOXAZOSIN VS DOXAZOSIN GITS IN PATIENTS 2 FORMS OF DOXAZOSIN IS COMPARED (STANDARD VS GITS). | | | |
| DAZ-NY-95-002 | Y | A PILOT STUDY OF DOXAZOSIN GITS AND TAMSULOSIN PROSTATIC TISSUE DISTRIBUTION. | DOXAZOSIN/TAMSULOSIN | No | B |
| DAZ-P-86-001 | | TO STUDY THE ANTI-HYPERTENSION EFFICACY AND SAFETY OF DOXAZOSIN WHEN ADMINISTERED ONCE A DAY TO PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-PAK-97-002 | | AN OPEN NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION IN CLINICAL PRACTICE . | | | |
| DAZ-PAK-97-002A | | AN OPEN NON - COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION IN CLINICAL PRACTICE. | | | |
| DAZ-PE-96-001 | | AN OPEN, NON COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. | | | |
| DAZ-PHI-89-001 | | THE EFFECTS OF DOXAZOSIN IN PATIENTS WITH ESSENTIAL HYPERTENSION. | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-PHI-90-002 | | DOXAZOSIN IN HYPERTENSION (AN OPEN EVALUATION IN CLINICAL PRACTICE SITUATION) | | | |
| DAZ-PL-90-001 | | SAFETY AND EFFICACY OF DOXAZOSIN IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION | | | |
| DAZ-RU-92-001 | | AN OPEN NON-COMPARATIVE STUDY OF THE EFFICACY AND SAFETY OF DAZ IN THE TREATMENT OF MILD TO MODERATE HYPERTENSIVE PATIENTS | | | |
| DAZ-S-87-002 | Y | EFFECT AND SAFETY OF DAZ AND ATENOLOL IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND ELEVATED SERUM CHOLESTEROL | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-S-90-002 | Y | A PARALLEL SINGLE BLIND STUDY OF THE INFLUENCE ON THE FIBRINOLYTIC SYSTEM BY DOXAZOSIN AND FELODIPINE ER IN PATIENTS WITH A DIAGNOSIS OF HYPERTENSION. | DOXAZOSIN /FELODIPINE ER | No | C |
| DAZ-SA-90-001 | | SAFETY AND EFFICACY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION | | | |
| DAZ-SA-92-001 | Y | A PARALLEL DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN 2MG AND/OR HYDROCHLOROTHIAZIDE 6.25 MG TABLETS IN THE TREATMENT OF UNCOMPLICATED MILD TO MODERATE HYPERTENSION IN ADULT MALE AND FEMALE BLACK SOUTH AFRICANS. | DOXAZOSIN /HYDROCHLOROTHIAZIDE | No | C |
| DAZ-SA-92-002 | Y | A SINGLE BLIND STUDY TO EVALUATE ONCE DAILY DOXAZOSIN VERSUS ENALAPRIL IN NON-INSULIN DEPENDENT DIABETIC HYPERTENSIVE PATIENTS | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-SF-87-001 | | EFFECTS OF A PROLONGED TREATMENT WITH DOXAZOSIN ON SERUM LIPIDS, GLUCOSE INSULIN AND URIC ACID LEVELS AS WELL AS BP ON HYPERTENSIVE PATIENTS | | | |
| DAZ-TR-94-001 | | A MULTICENTER STUDY OF DOXAZOSIN IN THE TREATMENT OF MILD TO MODERATE ESSENTIAL HYPERTENSIVE PATIENTS | | | |
| DAZ-TR-95-001 | | IVA MULTICENTER STUDY OF IN THE TREATMENT OF PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA | | | |
| DAZ-TW-88-001 | | AN OPEN NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION | | | |
| DAZ-TW-88-002 | | AN OPEN, NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION | | | |
| DAZ-TW-88-003 | | AN OPEN, NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION | | | |
| DAZ-TW-88-004 | | AN OPEN, NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-TW-88-005 | | AN OPEN, NON-COMPARATIVE STUDY OF DOXAZOSIN IN ESSENTIAL HYPERTENSION. | | | |
| DAZ-TW-92-001 | | AN OPEN, NON COMPARATIVE STUDY OF DAZ IN ESSENTIAL HYPERTENSION | | | |
| DAZ-TW-96-001 | Y | A SINGLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN VS PLACEBO IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN /PLACEBO | Yes | B |
| DAZ-TW-96-002 | Y | A DOUBLE BLIND STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN VS PLACEBO IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. | DOXAZOSIN /PLACEBO | Yes | B |
| DAZ-UK-85-003 | Y | A SINGLE-BLIND PARALLEL GROUP COMPARISON OF DOXAZOSIN TABLETS AND ATENOLOL TABLETS AS MONO-ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE DIABETICS | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-UK-85-015 | | TO STUDY THE EFFICACY AND SAFETY OF DOXAZOSIN GIVEN ONCE A DAY AS PART OF A MULTIPLE DRUG THERAPY IN PATIENTS WITH ESSENTIAL HYPERTENSION. | | | |
| DAZ-UK-85-016 | | TO EVALUATE THE EFFICACY AND SAFETY OF DOXAZOSIN IN PATIENTS WITH CO-EXISTING HYPERTENSION AND DIABETES MELLITUS | | | |
| DAZ-UK-86-001 | | A CLINICAL AND PHARMACOKINETIC STUDY OF DOXAZOSIN IN THE TREATMENT OF HYPERTENSION IN PATIENTS WITH RENAL IMPAIRMENT. | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-UK-86-002 | Y | TO EVALUATE THE EFFECTS OF SINGLE AND REPEATED DOSES OF DOXAZOSIN ON BP, HR AND 24 HOUR AMBULATORY EKG IN PATIENTS WITH ESSENTIAL HYPERTENSION. | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-UK-86-003 | | EFFICACY AND SAFETY OF DOXAZOSIN, GIVEN ONCE DAILY AS PART OF MULTIPLE DRUG THERAPY, IN PATIENTS WITH SEVERE AND/OR RESISTANT HYPERTENSION. | | | |
| DAZ-UK-87-006 | Y | TO COMPARE THE EFFECTS OF DOXAZOSIN VS ATENOLOL ON PLASMA LIPOPROTEIN COMPOSITION IN HYPERTENSION PATIENTS WITH NON-INSULIN DEPENDENT DIABETES MELLITUS | ATENOLOL /DOXAZOSIN | No | C |
| DAZ-UK-87-009 | Y | TO ASSESS THE ANTI-HYPERTENSION EFFECTS, TOLERATION AND SIDE EFFECTS PROFILE DURING TREATMENT WITH DOXAZOSIN ALONE, ENALAPRIL ALONE, DURING CONCURRENT TREATMENT WITH DRUGS AND ENALAPRIL | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-UK-87-010 | Y | TO ASSESS THE ANTI-HYPERTENSION EFFECTS, TOLERATION AND SIDE EFFECTS PROFILE DURING TREATMENT WITH DOXAZOSIN ALONE, INARLAPRIL ALONE AND DURING CONCURRENT TREATMENT WITH DOXAZOSIN AND ENARALAPRIL | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-UK-88-002 | | AN OPEN NON-COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF CARDURA IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION | | | |
| DAZ-UK-88-004 | | AN OPEN STUDY OF THE EFFECT OF DOXAZOSIN AS SOLE ANTIHYPERTENSIVE THERAPY ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS | | | |
| DAZ-UK-89-002 | | AN OPEN, NON COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF CARDURA (DAZ) IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE HYPERTENSION AND WITH/ WITHOUT CONCURRENT DISEASE | | | |
| DAZ-UK-89-002C | Y | CARDURA VS. BENDROFLUAZIDE IN MILD-MODERATE HYPERTENSION. | BENDROFLUAZIDE /DOXAZOSIN | No | C |
| DAZ-UK-89-003 | Y | TO COMPARE THE EFFECT OF DOXAZOSIN VS. PLACEBO ON BLOOD LIPIDS IN PATIENTS WITH HYPERLIPIDAEMIA; WHO HAVE ADHERED TO A DIETARY REGIMEN FOR THREE MONTHS PRIOR TO ENTRY INTO THE STUDY. | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-UK-89-004 | Y | A DOUBLE-BLIND PLACEBO CONTROLLED EVALUATION OF DOXAZOSIN IN ELDERLY PATIENTS WITH MODERATE HYPERTENSION AND OF ITS EFFECTION ON CEREBRAL AND MUSCLE BLOOD FLOW. | DOXAZOSIN /PLACEBO | Yes | C |
| DAZ-UK-90-001 | Y | EFFECTS OF DOXAZOSIN VS ATENOLOL ON BP RENAL FUNCTION AUTONOMIC TONE GLYCEMIC CONTROL PLATELET AGGREGATION AND LIPID METABOLISM IN IDDM PATIENTS WITH HYPERTENSION. | ATENOLOL /DOXAZOSIN /PLACEBO | No | C |
| DAZ-UK-90-002 | Y | THE EFFECT OF DOXAZOSIN IN COMPARISON TO METOPROLOL ON BP AND LIPID METABOLISM IN PATIENTS WITH ESSENTIAL HYPERTENSION. | DOXAZOSIN /METOPROLOL TARTRATE | No | C |
| DAZ-UK-90-003 | Y | AN OPEN CROSS-OVER STUDY OF DOXAZOSIN VERSUS ENALAPRIL ON THE EFFECTS OF LIPID METABOLISM AND INTRAVASCULAR LIPOLYSIS IN NON-INSULIN DEPENDENT DIABETIC PATIENTS WITH HYPERTENSION. | DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-UK-90-004 | | EFFICACY OF DOXAZOSIN ON BP AND LIPID PROFILE IN PATIENTS WITH HYPERTENSION. | | | |
| DAZ-UK-91-002 | | PILOT STUDY TO DETERMINE THE EFFECTS OF DAZ ON URINARY ALBUMIN EXCRETION AND ON VASCULAR REACTIVITY TO NORADRENALINE IN NON-HYPERTENSIVE INSULIN-DEPENDENT DIABETICS WITH MICRO-ALBUMINURIA | | | |
| DAZ-UK-91-003 | | DOXAZOSIN IN THE TREATMENT OF RESISTANT ESSENTIAL HYPERTENSION. | | | |
| DAZ-UK-91-004 | | PILOT STUDY TO DETERMINE THE EFFECTS OF DAZ OR URINARY ALBUMIN EXCRETION AND ON VASCULAR REACTIVITY TO NORADRENALINE IN HYPERTENSIVE INSULIN DEPENDENT DIABETICS | | | |

| | | | | | |
|---|---|---|---|---|---|
| DAZ-UK-93-001 | Y | A DOUBLE-BLIND PARALLEL GROUP MULTICENTRE STUDY COMPARING THE TOLERANCE AND EFFICACY OVER 24 HOURS OF DOXAZOSIN VS. AMLODIPINE ENALAPRIL AND BENDROFLUAZIDE (NOT PREVIOUSLY TREATED FOR AT LEAST A YEAR) AND TO ASSESS THE IMPACT OF AMBULATORY BLOOD PRESSURE | AMLODIPINE /BENDROFLUAZIDE /DOXAZOSIN /ENALAPRIL | No | C |
| DAZ-URU-97-001 | | DOXAZOSIN IN THE SYMPTOMATIC TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. AN OPEN BASELINE CONTROLLED STUDY. | | | |
| DAZ-VEN-96-001 | | DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. AN OPEN, MULTICENTRIC, BASELINE-CONTROLLED STUDY IN UROLOGIAL PRACTICE. | | | |
| DAZ-WAN-87-001 | | AN OPEN STUDY OF THE EFFICACY AND SAFETY OF DOXAZOSIN IN THE TREATMENT OF SEVERE ESSENTIAL HYPERTENSION | | | |
| L-0037 | Y | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND TRIAL OF DOXAZOSIN VS ATENOLOL AS INITIAL ANTIHYPERTENSIVE THERAPY | ATENOLOL | No | C |
| L-0298 | Y | A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL COMPARISON OF THE EFFECTS OF MONTHERAPY (GIVEN MORNING VS. EVENING) WITH DOXAZOSIN VERSUS TERAZOSIN ON OFFICE BLOOD PRESSURE, TWENTY-FOUR BLOOD PRESSURE CONTROL, AND SIDE EFFECT PROFILE IN PATIENTS WITH STAGE I AND II PRIMARY HYPERTENSION | DOXAZOSIN/PLACEBO/TERAZOSIN | Yes | C |
| L-0348 | | AN OPEN-LABEL STUDY OF DOXAZOSIN FOR THE TREATMENT OF CONCOMITANT HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA IN PATIENTS WHOSE BLOOD PRESSURE IS WELL-CONTROLLED ON ANTIHYPERTENSIVE MONOTHERAPY | | | |
| R-0075 | Y | A MULTICENTER EVALUATION OF THE EFFICACY AND SIDE EFFECT PROFILE OF DOXAZOSIN VS. HYDROCHOLOROTHIAZIDE AS INITIAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MILD-TO-MODERATE PRIMARY HYPERTENSION | DOXAZOSIN/HYDROCHLOROTHIAZIDE/PLACEBO | No | C |
| R-0105 | Y | A MULTICENTER EVALUATION OF THE EFFICACY AND SIDE EFFECT PROFILE OF DOXAZOSIN VS. ATENOLOL AS INITIAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MILD-TO-MODERATE PRIMARY HYPERTENSION | DOXAZOSIN/ATENOLOL/PLACEBO | No | C |
| R-0111 | Y | A MULTICENTER EVALUATION OF THE EFFICACY AND SIDE EFFECT PROFILE OF DOXAZOSIN VS. ENALAPRIL AS INITIAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH MILD-TO-MODERATE PRIMARY HYPERTENSION | DOXAZOSIN/ENALAPRIL/PLACEBO | No | C |
| R-0203 | Y | MULTICENTER, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFECTS OF ADDITION OF DOXAZOSIN TO THE THERAPEUTICREGIMEN ON BLOOD PRESSURE CONTROL IN HYPERTENSIVE PATS WHOARE NOT CONTROLLED ON THEIR CURRENT ANTIHYPERTENSIVE THERAPY | DOXAZOSIN/PLACEBO | Yes | C |
| R-0217 | Y | A M/C, D/B PARALLEL STUDY TO EVALUATE THE EFFECTS OF DOXAZOSIN VS HYDROCHLOROTHIAZIDE ON BLOOD PRESSURE CONTROL & SERUM LIPID PROFILE IN PTS W/PRIMARY (ESSENTIAL) HYPERTENSION & MODERATE ELEVATION OF TOTAL CHOLESTEROL FOLLOWING DIETARY MANAGEMENT | DOXAZOSIN/HYDROCHLOROTHIAZIDE/PLACEBO | No | C |
| R-0227 | Y | THE INFLUENCE OF ANTIHYPERTENSIVE THERAPY WITH EITHER DOXAZOSIN, ENALAPRIL, ATENOLOL, OR PLACEBO ON BLOOD PRESSURE CONTROL, INSULIN SENSITIVITY, LIPID PROFILE, CARDIOVASCULAR AUTONOMIC FUNCTION AND REACTIVITY, GLYCEMIC CONTROL AND SIDE EFFECT PROFILE IN BOTH NON-DIABETIC HYPERTENSIVES AND HYPERTENSIVES WITH TYPE II DIABETES MELLITUS TREATED WITH GLIPIZIDE | DOXAZOSIN/ATENOLOL/ENALAPRIL/PLACEBO | Yes | C |
| R-0264 | | A TWO SITE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOXAZOSIN IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION AND RENAL INSUFFICIENCY | | | |

| | | | | | |
|---|---|---|---|---|---|
| R-0387 | Y | A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL COMPARATIVE STUDY OF DOXAZOSIN VS. TERAZOSIN FOR THE TREATMENT OF BENIGN PROSTATIC HYPERLASIA IN NORMOTENSIVE PATIENTS, USING BOTH MORNING AND EVENING DOSING. | DOXAZOSIN/PLACEBO/TERAZOSIN | Yes | B |
| R-0388 | | A MULTI-CENTER OPEN-LABEL STUDY OF CARDURA (DOXAZOSIN MESYLATE) FOR THE TREATMENT OF PATIENTS WITH STAGE I (MILD) OR STAGE II (MODERATE) PRIMARY HYPERTENSION WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA | | | |
| R-0407 | Y | A DOUBLE BLIND, MULTICENTER, PLACEBO-CONTROLLED, PARALLEL COMPARISON OF THE EFFECTS OF DOXAZOSIN VERSUS LISINOPRIL, ALONE AND IN COMBINATION WITH HYDROCHLOROTHIAZIDE ON BLOOD PRESSURE CONTROL, RENAL FUNCTION AND SIDE EFFECT PROFILE IN BLACK PATIENTS WITH STAGE I AND STAGE II PRIMARY HYPERTENSION. | DOXAZOSIN/HYDROCHLOROTHIAZIDE/LISINOPRIL/PLACEBO | Yes | C |